Psychedelics Research

The Drug Enforcement Administration (DEA) has unveiled new production quotas for Schedule I and II controlled substances, with a notable emphasis on boosting the supply of certain psychedelics for research purposes. As Marijuana Moment reported, among the substances marked for increased production...

The National Institutes of Health (NIH) is stepping up efforts to combat the rising tide of methamphetamine addiction by funding a $2.4 million study to explore the potential of psychedelics as a treatment. According to Marijuana Moment, this five-year grant, provided by the National Institute on...

Welcome to a new episode of the Benzinga Psychedelics Podcast where we’re joined by Dr. Matthew X. Lowe, executive director and CSO to Unlimited Sciences, a Colorado-based nonprofit organization conducting and supporting research with psychedelics. Unlimited Sciences recently launched a toll-...

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024. See previous edition Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More Research Psilocybin for dementia prevention? The potential...

DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)....

Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three and six months ended February 29, 2024.  Q2 showed: Cash position of $4.8 (CA$6.6) million by February 29, 2024, compared to the $14.33...

Canadian licensed psychedelics pharmaceutical manufacturer Optimi Health Corp. (OTCQX:OPTHF) has signed an international agreement to supply natural psilocybin to New Zealand-based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.  The agreement marks Optimi’s first...

State-level psychedelics policy reform keeps moving forward throughout the U.S. Below is a recap of the moves that took place in the past three weeks (see the previous recap.) Missouri: Controversial budget proposal HB 2010 received final approval by the state's House on April 5, a day after it...

Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation of its DMT-based compound AP-188 for the potential treatment of stroke.  The research program has now become Algernon's lead drug asset,...

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024. See previous edition Psychedelics Headlines: Substitution Survey, Frank Herbert’s Magic Mushrooms, Celestial Plans And News Review Research Psychedelic...

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley’s novel formulation of 5-MeO-DMT in Treatment Resistant Depression...

Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023. The Numbers: Cash, cash equivalents and short-term investments of $154.2 million by December 31, 2023, as compared to $273.1 million by...

Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)  See: Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics...

The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the composition of matter of its lead novel compound, ALA-002.   The Novel Chemical Entity (NCE) is among the group of MDXX-class molecules under development by the biotech....

Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA’s potential effects on addiction treatment. PharmAla Signs...